IAEA activities in support of production and utilization of radioisotope labelled compounds

• Published in: Journal of labelled compounds & radiopharmaceuticals 2007-04, Vol.50 (5-6), p.312-317
• Main Authors: Ramamoorthy, Natesan, Pillai, Maroor Raghavan Ambikalmajan, Jin, Joon-Ha, Haji-Saeid, Seyed Mohammad
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Contrast media. Radiopharmaceuticals; labelled; Medical sciences; Pharmacology. Drug treatments; radioisotope; radiopharmaceutical; radiotracer
• ISSN: 0362-4803; 1099-1344
• DOI: 10.1002/jlcr.1203

The development of a large variety of radioisotope labelled compounds as well as the ability to design and prepare specific products forms the basis for several important applications in medicine, industry and research. As a part of the IAEA's role in fostering the peaceful uses of nuclear science and technology, the IAEA's Division of Physical and Chemical Sciences has focused attention on the important classes of compounds such as, fluorine‐18 products; technetium‐99m labelled complexes; products for radionuclide therapy of yttrium‐90, samarium‐153, lutetium‐177 and rhenium‐186/188; industrial radiotracers based on bromine‐82 labelled compounds, tritiated water and carbon‐14 labelled thiocyanate. A number of coordinated research projects (CRP) and technical cooperation projects have been implemented for this purpose. Thematic technical and consultancy meetings have been held to review the status and prepare technical documents on specific topics of interest for developing Member States (MS). These measures have contributed to several developing MS acquiring/enhancing expertise in building local facilities and capability in the production and utilization of radioisotope labelled compounds. Copyright © 2007 John Wiley & Sons, Ltd.